AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02958475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding messages
Description: The Mother's Milk Messaging app gives participants access to text messages via push notification on the app, as well as access to videos and written material to facilitate knowledge acquisition and skills building. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
Study NCT02958475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Injury Prevention Messages
Description: The Mother's Milk Messaging app will provide participants in the control group with genetic injury prevention message.
Study NCT03439397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ballon Technique
Description: Ballon Technique
Study NCT03439397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOAI
Description: SOAI
Study NCT04564859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heated Humidified High-Flow Nasal Cannula
Description: Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.
Study NCT04564859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated Humidified High-Flow Nasal Cannula
Description: Participants using of invasive ventilator more than 14 days, maybe considered transferred to the Respiratory Care Center(RCC), participants enrolled to this study and also written informed consent from participants or their family; After extubation, the difficult weaning patients were allocated to two treatment groups, and randomly assigned to Heated Humidified High-Flow Nasal Cannula or Noninvasive Ventilation devices.
Study NCT04414397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLUMA® XC
Description: JUVÉDERM® VOLUMA® XC injectable gel
Study NCT04414397 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® VOLUMA® XC
Description: JUVÉDERM® VOLUMA® XC injectable gel
Study NCT04414397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No-treatment control
Description: Participants received no treatment for 3 months during the Control Period.
Study NCT00130728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
Study NCT00130728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: erlotinib HCl
Description: oral erlotinib HCl 150 mg/day orally
Study NCT00130728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
Study NCT01130714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance training with resistance bands.
Study NCT00904722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-011
Description: Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).
Study NCT00904722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously at the standard dose of 375 mg/m\^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
Study NCT00053768 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Study NCT00053768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPOCH regimen
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH regimen
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT00053768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00053768 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT00053768 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02494453 — intervention group
Intervention type: PROCEDURE
Intervention: Research Cardiac MRI
Description: Cardiac MRI has increasing utility in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Thus, cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their treating physician. In this study, treatment will not be altered based on the data collected from these MRIs.
Study NCT02494453 — intervention group
Intervention type: PROCEDURE
Intervention: Biomarkers
Description: Scant data exist on potential biomarkers of cardiac radiation exposure and damage. However, we have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.~All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their treating physician. In this study, treatment will not be altered based upon the data collected from these samples.
Study NCT04136964 — intervention group
Intervention type: OTHER
Intervention: Neck COMI
Description: Patients will be asked to fill a questionnaire booklet consisting of five patient-reported outcome measures twice within 14 days.
Study NCT02262390 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partner Notification Reminders
Description: For all 3 arms, the following will be done:~* All participants will have an antenatal clinic visit every 4 weeks until delivery.~* All notification slips will be duplicate; one given to the mother and one held in the clinic. The study ID number will be documented on the slip. On partner return the slips will be matched and used to link mothers with male returning partners.~* Partner participant test result will be linked to the patient using the participant ID number in the lab. Partners will be tested using a rapid treponemal antibody test.
Study NCT03327077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live Preferential Music
Description: Trained musicians will play live preferential music to ED patients who consent to participate.
Study NCT02369588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food portion size
Study NCT02199249 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction Tightrope fixation
Description: Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
Study NCT02199249 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction screw fixation
Description: Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
Study NCT04382183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic weight loss maintenance diet
Description: The ketogenic weight loss maintenance group will undergo in a ketogenic diet (50 g CHO/day) plant-based for 1 year.
Study NCT04382183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Isocaloric balanced weight loss maintenance diet
Description: The isocaloric balanced weight loss maintenance group will undergo in a diet following the recommendations from the Norwegian Health Directorate for 1 year.
Study NCT03854214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Functional Electric Stimulation cycling
Description: The Functional Electrical Stimulation (FES) cycling group will use RT300 ergometer (Restorative Therapies, Inc). Bilateral glutei, quadriceps and hamstrings will be stimulated. The stimulation parameters will be set as follows: waveform biphasic, charged balanced; phase duration of 250 microseconds; pulse rate 33-45 pps. The stimulus intensity will be adjusted for individual patients and muscle group so that a tolerable stimulation is provided that will generate a cycling action. Target cycling speed is 50 RPM. Resistance will be automatically adjusted by the FES bike according to the subject's performance. When fatigue occurs, participants will continue cycling with electrical stimulation and motor support. FES therapy will be administered for one hour per session 3 times a week.
Study NCT03854214 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Passive cycling
Description: The passive cycling group will use the same RT300 ergometer however during this period stimulation will not be turned on. Instead, continuous motor support will be activated resulting in passive cycling. Target cycling speed is 50 RPM. Participants assigned to passive cycling will be required to have one hour of passive therapy 3 times a week for the entire duration of treatment assignment.
Study NCT04012099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMT101
Description: Intradermal injection to each of 3 dose-groups.
Study NCT04187963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: The rehabilitation protocol for the IPT consisted of cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises. In addition, the GPT protocol followed the exact same pattern, except for 5-10 minute breaks for informal socialization between participants, at the beginning of the session, mid-session and at the end of the session.~Also, both groups had access to external cues, which were applied during a variety of tasks and environmental situations, like gait initiation and termination, heel strike and push-off, sideways and backwards stepping, walking while dual tasking, and walking over various surfaces and long distances.
Study NCT04187963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: The rehabilitation protocol for the IPT consisted of cardiovascular warm-up activities, stretching exercises, strengthening exercises, functional, gait and balance training, recreational games and ended with relaxation exercises. In addition, the GPT protocol followed the exact same pattern, except for 5-10 minute breaks for informal socialization between participants, at the beginning of the session, mid-session and at the end of the session.~Also, both groups had access to external cues, which were applied during a variety of tasks and environmental situations, like gait initiation and termination, heel strike and push-off, sideways and backwards stepping, walking while dual tasking, and walking over various surfaces and long distances.
Study NCT03888261 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mind-Body Approaches for Medical Conditions
Description: The intervention programme of the present trial is delivered in a group-based format (15 participants per group) and overall applies three therapeutic components:~1. Contemplative practices~2. Psychoeducation~3. Dialogue, including therapist-group dialogue as well as participant-participant dialogue.
Study NCT01707706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
Study NCT01707706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
Study NCT01707706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
Study NCT04303871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Invasive blood pressure assessment by radial artery canulation
Description: radial artery canula used to measure central blood pressure compared to non invasive automated device to measure BP in pregnant females
Study NCT04303871 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Invasive blood pressure assessment by radial artery canulation
Description: radial artery canula used to measure central blood pressure compared to non invasive automated device to measure BP in pregnant females
Study NCT03998501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with Mindfulness Class
Description: The CBTm classes are five, 90-minute sessions focused on strategies to reduce symptoms of anxiety and depression.
Study NCT03529084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFG816
Description: It will be administered orally daily.
Study NCT03529084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib or gefitinib
Description: Investigator's choice between erlotinib or gefitinib. These will be locally sourced.~Erlotinib will be administered orally daily. Gefitinib will be administered orally daily.
Study NCT03028012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Study NCT03028012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Study NCT03028012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
Study NCT03793140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) Induction tx: Cycle 1 and 2: Treatment on Days 1-5 (Each cycle is 14 days). (Each Cycle is 14 days) Maintenance tx: All subsequent Cycles: Treatment with CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) on Days 1-5 (Each Cycle is 21 days)
Study NCT01455246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin + Meropenem
Description: Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of > 30 ml/min and \< 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of >50 ml/min, 10-50 ml/min, and \< 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
Study NCT01455246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of >50 ml/min, 10-50 ml/min, and \< 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
Study NCT01363297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m\^2 to 2.0 mg/m\^2.~Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m\^2.
Study NCT00743496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GD2 antibody
Description: Anti-GD2 antibody
Study NCT04116242 — intervention group
Intervention type: OTHER
Intervention: blood sampling for research purpose
Description: blood sampling for research purpose (about 30ml) taken by venepuncture or from intravenous catheters if already in place
Study NCT03445234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry
Description: 26 g/day freeze-dried powder, 2 weeks duration
Study NCT03445234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder
Study NCT03445234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: banana
Description: Acute ingestion of bananas 0.2 g carb/kg every 15 min exercise with water
Study NCT04116242 — intervention group
Intervention type: OTHER
Intervention: clinical data collection
Description: clinical data collection in order to document the stage of disease, the presence of infection and existing complications of cirrhosis (ascites, hepatic encephalopathy, renal dysfunction, pulmonary dysfunction) and concomitant disease. These data will be collected for clinical reasons as highly important in the context of patients with cirrhosis and possible decompensation or liver failure and will therefore not require additional time
Study NCT04116242 — intervention group
Intervention type: OTHER
Intervention: Health-related Questionnaires
Description: Health-related Questionnaires (Questionnaire_CLD) regarding sleep characteristics (Pittsburgh sleep Quality index, PSQI), daytime sleepiness (Epworth sleepiness scale, ESS), anxiety and depression (Hospital Anxiety and Depression Scale, HADS) and quality of life (EQ-5D-5L)
Study NCT04116242 — intervention group
Intervention type: OTHER
Intervention: Sampling other biological materials (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies)
Description: Other biological material (e.g. liver biopsies, liver resections, ascites, urine, gut biopsies) will only be investigated if sampled for clinical reasons and if excessive material is available that is not needed for clinical purpose.
Study NCT03277586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probio'Stick
Description: Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
Study NCT03445234 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: No banana
Description: water only
Study NCT03720145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle intervention including diet, sleep, exercise, relaxation and mindfulness
Study NCT03277586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identically formulated and packaged inactive substance
Study NCT03467789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary Vitamin D3 pre-treatment
Description: The daily dose of D3 will always be 10,000 IU/day. Total amounts of D3 supplementation given will be adjusted, based upon serum 25-hydroxy-D3 levels found at baseline. Duration of pretreatment will be 14 days if the D3 level is \< 31 ng/mL, and 5 days if the D3 level is > 31 ng/mL